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Searching to define diagnostic criteria for malignant and non-malignant pleural effusions, the differential 
diagnostic value of ferritin (FRT), haptoglobin (HP), a,-antitrypsin (q-AT), lactate dehydrogenase 
(LDH) and complement factors C3 and C4 were investigated prospectively in 100 consecutive patients 
with pleural effusions of various aetiologies. Pleural effusion FRT, C3 and C4 concentrations were found 
to be useful in differentiating exudates from transudates, so that transudates practically could be 
excluded in pleural effusion: serum FRT ratio lower than 0.5 and/or in pleural effusion values for C3 and 
C4 higher than 300 mg dl - ’ and 70 mg dl - ‘, respectively. A pleural effusion: serum C3 ratio greater 
than 2 is seen only in malignant effusions. No discriminative pleural: serum ratio could be found in FRT 
and C4 values capable of differentiating malignant from non-malignant effusions. Pleural effusion q-AT 
and LDH values were elevated in exudates, as compared with transudates, and had an excellent 
sensitivity and predictive value, but low specificity, in differentiating malignant from non-malignant 
effusions. Finally, the sensitivity, specificity and positive predictive value of pleural effusion Hp 
concentrations were lower than those of FRT and complement factors C3 and C4, respectively. 
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Introduction 
The differential diagnosis of pleural effusions of vari- 
ous aetiologies still remains a difficult clinical prob- 
lem. Moreover, the differentiation between malignant 
and non-malignant pleural effusions is of significant 
importance since the demonstration of the presence 
of malignant cells in such effusions is not always 
possible (1). Several biochemical markers have been 
evaluated so far to differentiate malignant and non- 
malignant effusions but with little success. Ferritin 
(FRT) has been tested and found to be useful in 
the diagnosis of malignant pleural and peritoneal 
effusions (1,7,X). Complement factors C3 and C4 
have also been tested in pleural effusions associated 
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with bronchogenic carcinoma (9-12), but proved to 
have no diagnostic value over non-malignant pleural 
effusions. 
The aim of the present study was to investigate 
the role of FRT, haptoglobin (HP), a,-antitrypsin 
(q-AT), lactate dehydrogenase (LDH) and the comp- 
lement factors, C3 and C4, in differentiating malig- 
nant from non-malignant pleural effusions in a 
relatively large number of patients, and establish the 
sensitivity, specificity and predictive values of these 
measurements by comparison with transudative 
pleural effusions. 
Patients and Methods 
PATIENTS 
One hundred consecutive patients with pleural effu- 
sions [71 males and 29 females, aged 32-92 years 
(median 65 years)], admitted to the University Hos- 
pital of Heraklion between the years 1991 and 1993, 
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TABLE 1. Underlying diseases in the three groups of patients with pleural effusion studied 
Patient group Underlying disease 
Number of 
patients 
A Malignant exudates 
B Non-malignant exudates 
C Transudates 
Lung cancer 
Ovarian cancer 
Stomach cancer 
Breast cancer 
Chronic lymphocytic leukaemia 
Lymphoma 
Leiomyosarcoma 
Bladder cancer 
Cancer of unknown primary origin 
Total 
Parapneumonic exudate 
Tuberculous 
Eosinophilic 
Other inflammatory exudates 
Total 
Congestive heart failure 
Chronic renal failure 
Liver cirrhosis 
Total 
31 
3 
1 
4 
2 
1 
1 
1 
3 
47 
17 
8 
4 
5 
39 
15 
2 
2 
19 
were examined prospectively. In 47 of these patients 
[31 males and 16 females, aged 32-81 years (median 
64 years)], a malignant pleural effusion was found 
(group A), as judged by the positive cytology of 
pleural fluid or pleural biopsy. Thirty-four patients 
[26 males and eight females, aged 35-92 years 
(median 63 years)], had exudative non-malignant 
pleural effusion (group B). The remaining 19 patients 
113 males and five females aged 60-86 years (median 
74 years)], had transudate pleural effusion (group C). 
Transudates were differentiated from exudates on the 
basis of Light’s criteria (2). The underlying diseases 
in the above three groups of patients are shown in 
Table 1. All patients were examined clinically, evalu- 
ated with the aid of the appropriate haematological 
and biochemical analysis, and followed-up for 2 years 
(median follow-up time 13 months). All non- 
malignant pleural effusions were followed-up for a 
lo-month period at least. No recurrence of malignan- 
cies were observed in these patients. Malignant pleu- 
ral effusions were confirmed by pleural biopsy and/or 
cytology. No cases of mesothelioma were included in 
the study. 
METHODS 
Matched serum and pleural fluid specimens were 
obtained from all patients and were examined for 
total protein, glucose, LDH, FRT, q-AT, Hp, cell 
count, pH and C3 and C4 concentrations using 
standard laboratory methods. Studies were per- 
formed in the central laboratories of University Hos- 
pital of Heraklion by scientists who were blind to 
clinical data. Bacterial cultures and cytological 
examinations were performed in all pleural effusions 
studied. 
STATISTICAL ANALYSIS 
Kruskall-Wallis non-parametric analysis was used to 
compare mean values among the three groups of 
subjects studied, since individual values were not 
normally distributed. A probability value less than 
5% was considered statistically significant. Sensitivity, 
specificity and predictive values were calculated using 
standard formulas. 
Results 
Pleural fluid FRT, complement factors C3 and C4, 
Hp, q-AT and LDH concentrations found in the 
patients studied are shown in Table 2. A statistically 
significant difference in FRT levels was noted 
between the pleural effusions of the three study 
groups. The higher concentrations were observed in 
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TABLE 2. Pleural fluid ferritin, haptoglobin, a,-antitrypsin, complement factors C3 and C4, 
and lactate hydrogenase (LDH) concentrations in the patients studied 
Effusion 
Parameter studied 
Malignant 
(grow A) 
Non-malignant 
(grow B) 
Transudate 
(grow C> 
Ferritin (ng ml - ‘) 
Haptoglobin (mg dl - ‘) 
a,-Antitryspin (mg dl - ‘) 
C3 (mg dl - ‘) 
C4 (mg dl- ‘) 
LDH (IU 1 - ‘) 
1976 & 310 
“PiO.001 
tP<O.ool 
123.5 -f 17.8 
“P<O.OOl 
j-N.S. 
281 f 18 
“PcO.02 
j-P<O-05 
815 f 98 
“PCO.05 
7N.S. 
134 + 14 
*p<o-005 
j-N.S. 
469 I!Z 72 
*p<o*oo1 
PN.S. 
644 f 122 
*p<o.o01 
97.5 zt 12.7 
*p<o.o1 
231 f 12 
*p<o.o1 
712 f 107 
“N.S. 
142 f 17 
TP<O.O03 
393 f 96 
*p<omo1 
183 Lt 37 
47.7 & 9.7 
179f26 
291 f 48 
77 f 16 
67f 11 
Values are expressed as means f 1 standard error. 
“Comparison to the respective values in transudate (group C); -/Comparison to the 
respective values in non-malignant effusions (group B). 
group A. Complement C3 values were significantly 
different only between group A and group C, while 
C4 concentrations were significantly elevated in both 
A and B groups, as compared with C4 values in group 
C. Similarly, LDH levels were significantly increased 
in groups A and B, as compared with group C, but 
there was no significant difference between groups A 
and B. Hp and q-AT values were also both signifi- 
cantly higher in groups A and B than in group C, 
while there was no significant difference between 
groups A and B. 
The mean ratio of pleural fluid: serum concen- 
trations of FRT, complement factors C3 and C4, Hp, 
a,-AT and LDH are shown in Table 3. With the 
exception of complement factor C4, a significant 
increase was found in groups A or B in all parameters 
studied, as compared with the respective ratios seen in 
group C. 
exudates. Thus, FRT may be a good marker for 
distinguishing exudates from transudates with a rela- 
tively low sensitivity ranging from 59 to 68% in the 
three groups, but a very high specificity and positive 
predictive value (both 100%). A higher sensitivity was 
found between the same groups concerning the comp- 
lement factor C3 levels exceeding 300 mg 1 - i which 
ranged from 88.6 to 92.6%. The sensitivity of comp- 
lement factor C4 at the cut-off value of 70 mg 1 - ’ 
ranged from 76.9 to 100%. Both C3 and C4 had 
excellent specificity and positive predictive values 
between the studied groups of patients. a,-AT for the 
cut-off value of 150 mg dl - ’ proved to have high 
sensitivity (91.6-100°/), low specificity (63.5%) and a 
good predictive value (84.5-92.5%). Hp at the cut-off 
level of 70 mg dl - ’ had lower sensitivity and higher 
specificity than al-AT, but comparable positive 
predictive value. 
Table 4 illustrates the ,sensitivity, specificity and Table 5 shows the sensitivity, specificity and posi- 
positive predictive value of pleural effusion markers, tive predictive value of pleural effusion FRT, Hp, 
Pleural fluid FRT concentrations exceeding a,-AT and complement factors C3 and C4 ratio. For 
lOOOngm-’ were observed oniy in patients with the discriminative ratio of 0.6, FRT sensitivity was 
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TABLE 3. Mean ratio of pleural fluid to serum concentration of ferritin, haptoglobin, 
a,-antitrypsin, complement factors C3 and C4, and lactate hydrogenase (LDH) in the 
patients studied 
Effusion 
Pleural fluid to Malignant 
serum ratio (grow 4 
Non-malignant 
(group W 
Transudate 
(group C> 
Ferritin (ng ml - ‘) 
Haptoglobin (mg dl - ‘) 
a,-antitryspin (mg dl - ‘) 
C3 (mg dl ~ ‘) 
C4 (mg dl - ‘) 
LDH (IU 1 - ‘) 
5.5 + 1.3 
“WO.01 
N.S. 
0.36 f 0.05 
“WO.01 
PN.S. 
0.69 f 0.04 
“P<O.Ol 
N.S. 
0.10 * 0.22 
“P<O.OOl 
TN.S. 
0.30 f 0.10 
“N.S. 
7N.S. 
1.70 f 0.20 
“P<O.OOl 
“rN.S. 
6.5 f 1.3 
*p<o.o1 
0.30 zk 0.03 
*p<o.o4 
0.70 zt 0.03 
*p<o.o1 
0.58 5 0.20 
PCO.01 
0.30 f 0.13 
7N.S. 
2.30 f 0.50 
“P<O.OOl 
2.1 f 0.6 
0.20 It 0.02 
0.50 xt 0.06 
0.30 f 0.06 
0.30 Yt 0.20 
0.30 * 0.10 
Ratio values are expressed as means & 1 standard error. 
*Comparison to the respective ratio in transudates (group C); ?-Comparison to the 
respective ratio in non-malignant effusions (group B). 
much higher than previously described and ranged 
from 93.6 to 100%. However, the specificity was low 
(52.5%), while the positive predictive value was better 
(84.5-92.8%). A ratio of pleural fluid: serum C3 of 0.5 
was found to have low sensitivity (51.8-53.8%), while 
a ratio of 0.3 for the C4 was better, but relatively 
low in terms of specificity (69981.5%). However, 
both C3 and C4 ratios for the above values had 
excellent specificity and positive predictive values 
(100%). The q-AT ratio of 0.6 had a sensitivity 
ranging between 75 and 83% in the three study 
groups, a specificity of 72%, and positive predictive 
value between 85.5 and 93.5%. A Hp ratio of 0.25 had 
a lower sensitivity than q-AT (range from 66.5 
to 79%) and comparable specificity and positive pre- 
dictive values. 
Finally, considerable overlap was observed in levels 
and ratios of all studied markers in our patients with 
benign (group B) vs. malignant (group A) pleural 
effusion due to low specificity and positive predictive 
value between these two groups. 
Discussion 
The distinction between malignant and non- 
malignant pleural effusions is often difficult in medi- 
cal practice. Various biochemical markers have been 
employed to identify malignant effusions (1,668). 
Increased concentrations of FRT, a 450 kDa iron 
storage protein, have been found in serum and bio- 
logical fluids of patients with a variety of malignan- 
cies (1,3,4). It has been proposed that these increased 
concentrations might be due to an enhancement of its 
synthesis, stimulated by the tumour cells, especially in 
the case of liver metastasis (1). Furthermore, tumour 
necrosis factor was found to increase the synthesis of 
subunit H of FRT, which was totally independent 
of iron’ stimulation (5). In the present study, FRT 
concentrations were significantly elevated in patients 
with malignant pleural fluid. For the cut-off value of 
1000 ng dl~ ‘, it was found to be significantly higher 
in group A vs. groups B and C (P<O.OOl and 
P<O.OOl, respectively). Although, the specificity and 
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TABLE 4. Discriminative values of ferritin, haptoglobin, a,-antitrypsin and complement 
factors C3 and C4 in transudates and exudates 
Transudates 
VS. 
all 
exudates 
Transudates 
VS. 
malignant exudates 
Transudates 
VS. 
non-malignant 
exudates 
Ferritin > 1000 ng ml - ’ 
Sensitivity 62.9% 
Specificity 100.0% 
PP value* 100.0% 
C3 >300 mgdl-’ 
Sensitivity 90.6% 
Specificity 100.0% 
PP value 100.0% 
C4 >700mgdll’ 
Sensitivity 88.7% 
Specificity 100.0% 
PP value 100.0% 
a,-antitrypsin > 150 mg dl ~ ’ 
Sensitivity 98.0% 
Specificity 63.6% 
PP value 92.7% 
Haptoglobin >70 mg dl - ’ 
Sensitivity 75.0% 
Specificity 73.0% 
PP value 92.8% 
68.0% 58.9% 
100.0% 100.0% 
100.0% 100.0% 
92.6% 88.5% 
100.0% 100.0% 
100.0% 100.0% 
100.0% 76.9% 
100.0% 100.0% 
100.0% 100.0% 
100.0% 91.6% 
63.6% 63.6% 
87.5% 84.6% 
82.0% 62.5% 
73.0% 73.0% 
88.0% 83.0% 
*PP value, positive predictive value. 
positive predictive value was excellent (100%) the 
sensitivity was relatively low (59-68%) (Table 4). The 
lower levels were found in transudates. However, 
significant overlap was found between groups A and 
B. For a pleural effusion: serum ratio below 0.5, 
transudates are practically excluded. No discrimi- 
native ratio for groups A and B were found due 
probably to overlap. This finding is in contrast with 
that of Yinnon et al. (1) who reported that a ratio 
greater than 20 is seen only in malignant pleural 
effusions. 
Both C3 and C4 complement factors were found to 
have sensitivity, specificity and positive predictive 
value higher than FRT (Table 4). Values for C3 
higher than 300 mg dl- ‘, and C4 higher than 
70 mg dl - ’ were found only in patients of groups A 
and B, practically excluding transudate pleural 
effusion. However, considerable overlap was found 
between groups A and B. A C3 ratio greater than 2 
was found only in malignant pleural effusions. 
Furthermore, a greater than 0.5 ratio excluded 
transudative pleural effusion. Regarding C4, a ratio 
greater than 0.3 excludes transudates, but consider- 
able overlap exists between malignant and benign 
effusions. 
Early studies found uniformly high levels of LDH 
in malignant effusions and low levels in non- 
malignant ones (13), but subsequent observations 
failed to confirm this suggestion (14). In the present 
study, elevated LDH values were found in both 
malignant and non-malignant exudates, as compared 
with those found in transudates. No difference 
was found between malignant and non-malignant 
exudates. Thus, pleural effusion LDH levels may 
be useful only in differentiating exudates from 
transudates. 
al-AT is a glycoprotein synthesized in the liver. It 
has been suggested that high concentrations of al-AT 
are found in malignant but not in non-malignant 
ascitic fluids (15). The present findings show that 
al-AT is significantly elevated in cases of malignant 
pleural exudates as compared with non-malignant 
effusions (PcO.05) and transudates (WO.02). How- 
ever, significant overlap of values was found between 
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TABLE 5. Discriminative ratios of ferritin, haptoglobin, a,-antitrypsin and complement 
factors C3 and C4 in transudates and exudates 
Transudates 
VS. 
all 
exudates 
Transudates 
VS. 
malignant exudates 
Transudates 
VS. 
non-malignant 
exudates 
Ferritin >0*6 
Sensitivity 
Specificity 
PP value 
c3 >0.5 
Sensitivity 
Specificity 
PP value* 
c4 >0.3 
Sensitivity 
Specificity 
PP value 
a,-antitrypsin >0.6 
Sensitivity 
Specificity 
PP value 
Haptoglobin >70.25 
Sensitivity 
Specificity 
PP value 
96.3% 93.6% 100.0% 
52.6% 52.6% 52.6% 
92.8% 84.6% 85.4% 
52.8% 
00.0% 
00.0% 
1 
1 
51.8% 
00.0% 
00.0% 
53.8% 
100.0% 
100.0% 
75.5% 
00.0% 
00.0% 
1 
1 
81.5% 69.2% 
00.0% 100.0% 
00.0% 100.0% 
83.0% 
72.0% 
93.6% 
79.0% 
82.0% 
95.0% 
82.9% 75.0% 
72.0% 72.0% 
88.5% 85.5% 
71.5% 66.6% 
82.0% 82.0% 
91.0% 89.0% 
*PP value, positive predictive value. 
groups A and B. Pleural effusion a,-AT values have 
excellent sensitivity and positive predictive value, but 
low specificity (63.6%). No significant differences 
were noted between malignant and non-malignant 
effusions regarding the pleural effusion: serum q-AT 
values. Thus, pleural effusion q-AT values may be 
useful in distinguishing transudates from exudates 
but not in differentiating malignant from non- 
malignant effusions. 
Pleural effusion Hp values were also found to be 
significantly elevated in exudates, as compared with 
transudates. Hp is mainly derived from the liver, but 
some tumours can produce Hp as well (16,17). No 
significant differences were noted between malignant 
and non-malignant exudates. For the cut-off value of 
70mgdlK’, the sensitivity, specificity and positive 
predictive value of pleural effusion Hp concentrations 
were lower than those of FRT and complement 
factors C3 and C4, respectively. 
In conclusion, pleural effusion FRT, C3 and C4 
concentrations are useful in differentiating exudates 
from transudates, so that transudates practically 
could be excluded in a pleural effusion: serum FRT 
ratio lower than 0.5 and/or in pleural effusion values 
for C3 and C4 higher than 300 mg dl - i and 
70mgdll’, respectively. A pleural effusion: serum 
C3 ratio greater than 2 is seen only in malignant 
pleural effusions. No discriminative pleural effusion: 
serum ratio could be found in FRT and C4 values 
capable of differentiating malignant from non- 
malignant effusions. Pleural effusion q-AT, Hp and 
LDH values are elevated in exudates, as compared 
with transudates, but they have low specificity for 
diagnosis of malignant exudates. 
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